Infinity Pharmaceuticals, Inc. (INFI) Misses Q4 EPS by 11c; Issues FY12 Loss Outlook
Tweet
Share
E-mailGet Alerts INFI Hot Sheet
Join SI Premium – FREE
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported Q4 EPS of ($0.53), $0.11 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $0 versus the consensus estimate of $23.77 million.
Infinity Pharmaceuticals, Inc. sees FY2012 EPS of $-1.30-$-1.70, versus the consensus of $-1.46.
For earnings history and earnings-related data on Infinity Pharmaceuticals, Inc. (INFI) click here.
Infinity Pharmaceuticals, Inc. sees FY2012 EPS of $-1.30-$-1.70, versus the consensus of $-1.46.
For earnings history and earnings-related data on Infinity Pharmaceuticals, Inc. (INFI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Burry doubles down on Nebius short after stock surges 34% on earnings
- MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
- Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
